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Introduction
 Current evidence supports the idea that many neurodegenerative 
diseases share specific features with prion diseases. Molecular 
mechanisms consisting of aggregation and spreading of misfolded 
proteins that are characteristic for each of them show similarities and, 
as a result, they have been included in a prion-like disease group [1]. 
Stanley Prusiner, the first scientist to identify the unique characteris-
tics of prion disease, has even applied the term ‘prion’ to the specific 
aberrant proteins in each of these diseases that are the pathological 
hallmark, including β-amyloid in Alzheimer’s and α-synuclein in 
Parkinson’s disease [2,3]. At microscopic level, all these disorders 
show histopathological insults such as amyloid deposits, neuronal 
loss, neurite degeneration and gliosis. The present study is particularly 
focused on contributing to knowledge concerning the latter-gliosis.
 Astroglia were initially thought to simply support neurons. More 
recent research has demonstrated they are essential for correct 
functioning of the Central Nervous System (CNS). Astrocytes are a 
cooperative component with neurons in the physiology, metabolism 
and homeostasis. They play a critical role in establishment of the 
Blood Brain Barrier (BBB), embryological CNS development, 
neurotransmission, and tripartite synapsis [4-9]. The other glial cell 
type, microglia are the main immune cells in CNS [10,11]. In response 
to any CNS injury, a glial multicellular response is detectable [12]. 
Specifically in regards to neurodegenerative disease, an association 
between reactive astroglia and / or microglia with aberrant protein 
deposits has been described [13-16]. However, in our opinion, the role 
of these cellular populations in the neurodegenerative process has not 
been sufficiently elucidated. Astroglial and microglial subpopulations 
may have dual roles in the neurodegenerative disorders, exerting both 
neuroprotective and neurotoxic effects in CNS [6,11,17].
 The present study was initiated as a result of our interesting 
findings concerning involvement of glial cells in neurodegeneration 
in sheep affected with Scrapie, a natural prion disorder [18,19]. The 
main aim of the study here was to compare and contrast morpho-
logical alterations of glial cells in cerebella from Creutzfeldt-Jakob 
Disease (CJD, as the most common prion disorder) and Alzheimer’s 
Disease (AD, as the most common prion-like disorder) as revealed by 




 This study was performed on sagittal sections of cerebellar samples 
from 10 CJD (Spanish brain bank from Hospital Universitario 
Fundación Alcorcón, Madrid) and 10 AD (Hospital Universitario 
Gregorio Marañón or Psiquiátrico de Ciempozuelos from Madrid) 
patients. All Cerebellar sections included a representative area from 
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 Several neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s and Huntington’s are considered to be prion-like 
disorders in that they are all proteinopathies where in aberrant 
proteins spread throughout the brain during disease progression, 
and thus they may share molecular basis and mechanisms of 
propagation. Therefore, studies elucidating mechanisms of prion 
propagation may be relevant to other neurodegenerative 
diseases. While substantial progress has been made, the pathogen-
esis of these neurodegenerative diseases is still largely unknown, 
and as consequence, to date no truly effective treatments that 
prevent onset or delay progression of these diseases have been 
identified. In addition to propagation of misfolded proteins, these 
diseases all induce a host response that includes activation of 
astrocytes and microglial cells. However, in our opinion, the glial 
response in each of these diseases has not been well-defined.
 Since a role for glial response in prion disease has been clearly 
demonstrated in a previous study concerning Scrapie in sheep, a 
similar approach to analysis of astrocytic gliosis has been taken here 
for Creutzfeldt-Jakob (CJD) and Alzheimer’s Diseases (AD). Here, 
morphological analysis of glial cells in cerebella from CJD and AD 
patients (as the most common prion and prion-like disorders, 
respectively) was performed.
 The results presented in this study support the involvement 
of glial cells not only in the pathogenesis of CJD, but also of AD. 
A relationship between intensity and morphology is observed in 
astroglia from the molecular layer in both pathologies. By contrast, 
the involvement of microgliosis in AD-affected samples showed a 
lower relevance from that observed in CJD, since reactive microglia 
were much more abundant in prion disease.
 Further analysis of the role of gliosis in CJD and AD, as well as 
other neurodegenerative diseases, may well advance knowledge of 
the mechanisms underlying these diseases and may also provide 
new targets for therapeutic intervention.
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molecular, Purkinje cell and granular layers, and white matter. All 
tissues were all formalin-fixed, formic acid inactivated for 1 hour, 
paraffin embedded, sectioned at 4-5 µm, and mounted on Vectabond 
pre-treated glass slides. The immunohistochemical protocols, as 
follows, were then performed on tissue sections after overnight 
incubation at 56°C and deparaffinization through graded alcohols.
GFAP immunohistochemistry
 After endogenous peroxidase inactivation by incubation of sections 
with peroxidase blocking reagent (DAKO, Hamburg, Germany) for 
5 min, sections were incubated with a monoclonal primary antibody 
against glial fibrillary acidic protein (GFAP, 1/500, 30 min RT; DAKO, 
Hamburg, Germany) followed by incubation with enzyme-conjugat-
ed polymer EnvisionTM - labeled rabbit secondary antibody (30 min, 
RT; DAKO Hamburg, Germany). Labeling was performed using DAB 
PLUS (10 min) as chromogen.
 Morphology and intensity (high, medium, or low) of GFAP 
immunostaining were assessed in each layer from all the cerebella.
Reactive microglia immunohistochemistry
 For reactive microglia labeling, the protocol was the same as 
that for GFAP, but CD68 and MHCII primary antibodies were used 
(1/500 and 1/200, respectively; DAKO Hamburg, Germany) and the 
incubation was 30 min at RT.
 Morphology and intensity (high, medium, or low) of reactive 




 While the focus of this study was morphology, the intensity 
of GFAP immunostaining for the AD and CJD samples was also 
classified as described above: high, medium, or low intensity. The fol-
lowing astrocytic morphologies were consistently observed in samples 
from both CJD and AD patients, and consisted of three main findings: 
first, GFAP immunolabeling was increased around Purkinje cells 
(Figure 1); second, fibrillar labeling in the molecular layer 
corresponding to radial (Bergmann) glial labeling, and third, a 
horizontal astroglial profile. The radial glia labeling was found in those 
samples with high GFAP intensity and, conversely, the horizontal glia 
labeling in those with a low GFAP intensity (Figure 2).
 GFAP immunolabeling was consistently detected in association 
with protein aggregates in both, AD and CJD tissues (Figure 3). Also 
in both CJD and AD tissue, GFAP immunolabeling appeared next to 
the meninges in many occasions (Figure 4).
Reactive microglia immunostaining
 Both ramified and amoeboid activated microglia was detected in 
all cerebellar layers from all CJD samples. In contrast, little microglia 
activation was seen in AD tissues. Only in two AD samples was some 
microgliosis detected, and it was mostly limited to white matter and 
presenting ramified morphology (Figure 5).
Discussion
 Both astrogliosis and microglial activation consistently appear in 
brain tissue from patients suffering from neurodegenerative disease 
[6,8,12]. Despite constituting a universal finding across many 
Figure 1: GFAP detection by immunohistochemistry in cerebella from AD 
(A), CJD (B) and control (C) cases show an evident increase of immunolabel-
ing around Purkinje cells.
Figure 2: GFAP immunolabeling in cerebella evidenced two different astroglial 
profiles in the molecular layer from samples affected by both pathologies, AD 
(A and C) and CJD (B and D), respectively: a radial profile when high GFAP 
intensity (A and B) or a horizontal profile when lower GFAP intensity were 
detected (C and D). GFAP immunolabeling in cerebella from control cases 
are also showed.
Figure 3: GFAP immunolabeling was always detected in association with 
protein aggregates in AD (A) and CJD (B) samples.
Figure 4: GFAP immunostaining appeared next to meninges in AD (A) and 
CJD (B) cerebella in many occasions.
Figure 5: Reactive microglia immunostaining in cerebellum differs depending 
on the pathology studied: scarce, mostly ramified and located in white 
matter from AD samples (A); or abundant, combined ramified -amoeboid and 
extended over all the layers from CJD patients (B).
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neurodegenerative diseases, there has not been the focus on this 
response that is afforded the proteins that are implicated in each 
disease. The present study constitutes a preliminary approach to 
determine whether glial changes observed in a human prion disease, 
CJD, agree with those observed in the most prevalent prion - like 
disease, AD. To our knowledge, this is the first morphological study 
performed with the aim to compare the specific alterations of glial 
cells in these two neurodegenerative diseases. We focused on 
microglia and astroglia, due to their roles in immune function 
and therefore, in neuroinflammation. Neuroinflammation itself is 
considered either causative or contributory to the pathogenesis of 
neurodegeneration [6,20].
 Cerebellum is a brain area affected in all CJD patients, but in 
AD patient involvement of this area is less evident. However, results 
presented here indicate that astroglia show similar morphological 
changes in cerebellum from patients suffering either pathology. 
Labeling around Purkinje cells had been seen previously in Scra-
pie-affected sheep [19] and is seen again here in both CJD and AD. In 
cerebella from AD affected patients, neuronal loss and astrocyto-
sis has previously been assessed, but in that study only familial and 
sporadic AD were compared [21]. The demonstration here that Pur-
kinje cells are the most ‘protected’ neurons have been evidenced by 
ultrastructural studies in Scrapie, where they were revealed to be 
the most damaged neurons too. Vacuolation preferentially occurred 
around these neurons [22]. This finding indicates that the normally 
protective role of astrocytes may become deleterious in advanced 
disease.
 Similar findings pointing to Purkinje neurons as playing a 
role have been reported for Guam disease or Amyotrophic lateral 
sclerosis / Parkinsonism-dementia complex [23]. As a whole, Purkinje 
cells appear to constitute one main target of neurodegeneration, not 
only in prion but also in prion-like diseases. Further studies focused 
on the interaction between this neuronal population and astroglia 
are being currently undertaken in order to elucidate this finding. 
Astrocytic ability to protect but also damage neurons might explain 
that the neurodegenerative progress is found closely associated to 
these glial cells.
 Another notable observation here consists of the relationship 
between intensity and morphology observed in astroglia from the 
molecular layer. The intense radial gliosis observed in samples 
showing higher GFAP intensity suggests an advanced stage of the 
disease in agreement with conclusions provided in the Scrapie model 
[19]. Those samples showing a lower GFAP intensity showed a 
decrease of radial morphology while a different horizontal 
morphology appeared instead; they could correspond to an earlier 
stage of the disease based on the observations described in the study 
developed in the Scrapie model cited above. Cerebellar radial glia are 
used as ‘scaffolds’ guiding neuroprogenitor cells during development. 
This could suggest a glial stem cell response with the aim of 
compensating for neuronal loss, as previously proposed [9] on the 
basis of the evidence of that radial glial cell are important progenitor 
cells that contribute to gliogenesis. Furthermore, the relevance of 
studies developed in prion naturally affected animals is confirmed 
here as a reliable tool for helping to understand observations in 
affected human samples. Unlike in human disease, studies of Scrapie 
in sheep allow variable to be controlled and disease progress defined; 
the results of these studies may be extrapolated and provide useful 
information in regard to human disease. This association would 
predict what is happening in the neurodegenerative progress affecting 
humans.
 By contrast, the involvement of microgliosis in AD affected 
samples differed greatly from that observed in CJD. Microglial 
activation appears to be less relevant in cerebellar tissue in AD than 
in CJD since reactive microglia were much more abundant in prion 
disease. However, other studies have indicated a higher significance 
for the role of microglia in AD. This could be explained due to the 
brain area studied or to the close relationship of this glial population 
with misfolded protein deposits or plaque - associated phagocytic 
activity, in prion disease [16] as well as in AD [24]. Thus, 
microglial activation is likely of greater significance in areas of brain 
wherein protein aggregates are found in AD, such as the hippocam-
pus and cortex. Additional studies focused on further brain areas are 
planned in order to confirm this hypothesis.
 The aggregation and spreading of aberrant proteins in prion and 
prion-like disease triggers a glial response. This glial response may 
itself impact the onset, progression, and severity of disease. To fully 
reveal the pathogenesis of prion and prion-like disease, there should 
be continued focus on both the astrocytic and microglial response to 
disease.
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